Medication Guide App

Concerta (methylphenidate) Disease Interactions

There are 8 disease interactions with Concerta (methylphenidate):

Cns Stimulants (Includes Concerta) ↔ Agitation

Severe Potential Hazard, High plausibility

Applies to: Anxiety/Stress, Neurosis, Psychosis

The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.

References

  1. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  2. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
View all 11 references

Cns Stimulants (Includes Concerta) ↔ Substance Abuse

Severe Potential Hazard, High plausibility

Applies to: Alcoholism, Drug Abuse/Dependence

Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.

References

  1. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
View all 11 references

Methylphenidate (Includes Concerta) ↔ Glaucoma

Severe Potential Hazard, Moderate plausibility

Applies to: Glaucoma/Intraocular Hypertension, Glaucoma (Narrow Angle)

The use of methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. These agents exhibit sympathomimetic activity and may induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, methylphenidate should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.

Methylphenidate (Includes Concerta) ↔ Hypertension

Severe Potential Hazard, High plausibility

Applies to: Hypertension

Methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer) exhibit sympathomimetic activity and may elevate blood pressure and pulse rate. Therapy with these agents should be administered cautiously in patients with hypertension. Blood pressure should be monitored periodically during therapy.

References

  1. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.

Methylphenidate (Includes Concerta) ↔ Seizures Disorders

Severe Potential Hazard, High plausibility

Applies to: Seizures

There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures. The medication should be discontinued if seizures occur during its use.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.

Cns Stimulants (Includes Concerta) ↔ Tics

Moderate Potential Hazard, High plausibility

Applies to: Tic Disorder

Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
View all 11 references

Methylphenidate (Includes Concerta) ↔ Hematologic Toxicity

Moderate Potential Hazard, Low plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate. However, a causal relationship has not been established. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.

References

  1. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.

Methylphenidate Er (Includes Concerta) ↔ Gi Narrowing

Moderate Potential Hazard, High plausibility

Applies to: Gastrointestinal Obstruction

The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material. There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products. The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel's diverticulum). The medication should only be used in patients who are able to swallow the tablet whole.

References

  1. "Product Information. Concerta (methylphenidate)." Alza, Palo Alto, CA.

You should also know about...

Concerta (methylphenidate) drug Interactions

There are 403 drug interactions with Concerta (methylphenidate)

Concerta (methylphenidate) alcohol/food Interactions

There are 3 alcohol/food interactions with Concerta (methylphenidate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2014 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)